Atenção:
O eduCAPES é um repositório de objetos educacionais, não sendo responsável por materiais de terceiros submetidos na plataforma. O usuário assume ampla e total responsabilidade quanto à originalidade, à titularidade e ao conteúdo, citações de obras consultadas, referências e outros elementos que fazem parte do material que deseja submeter. Recomendamos que se reporte diretamente ao(s) autor(es), indicando qual parte do material foi considerada imprópria (cite página e parágrafo) e justificando sua denúncia.
Caso seja o autor original de algum material publicado indevidamente ou sem autorização, será necessário que se identifique informando nome completo, CPF e data de nascimento. Caso possua uma decisão judicial para retirada do material, solicitamos que informe o link de acesso ao documento, bem como quaisquer dados necessários ao acesso, no campo abaixo.
Todas as denúncias são sigilosas e sua identidade será preservada. Os campos nome e e-mail são de preenchimento opcional. Porém, ao deixar de informar seu e-mail, um possível retorno será inviabilizado e/ou sua denúncia poderá ser desconsiderada no caso de necessitar de informações complementares.
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.contributor | Universidade Estadual Paulista (UNESP) | - |
Autor(es): dc.contributor | Clinical Hospital at Botucatu School of Medicine-HC-FMB | - |
Autor(es): dc.contributor | Universidade de São Paulo (USP) | - |
Autor(es): dc.contributor | General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area) | - |
Autor(es): dc.creator | Oliveira Ribeiro, Michele Costa de | - |
Autor(es): dc.creator | Moda, Kerolyn Adorne | - |
Autor(es): dc.creator | Alvarez, Matheus | - |
Autor(es): dc.creator | Koga, Katia Hiromoto | - |
Autor(es): dc.creator | Moriguchi, Sônia Marta | - |
Autor(es): dc.creator | Carvalho, Fábio Cardoso | - |
Autor(es): dc.creator | Pinheiro, Rafael Soares Nunes | - |
Autor(es): dc.creator | Qi, Xingshun | - |
Autor(es): dc.creator | Romeiro, Fernando Gomes | - |
Data de aceite: dc.date.accessioned | 2025-08-21T23:08:59Z | - |
Data de disponibilização: dc.date.available | 2025-08-21T23:08:59Z | - |
Data de envio: dc.date.issued | 2025-04-29 | - |
Data de envio: dc.date.issued | 2024-05-01 | - |
Fonte completa do material: dc.identifier | http://dx.doi.org/10.1016/j.acra.2023.10.029 | - |
Fonte completa do material: dc.identifier | https://hdl.handle.net/11449/305708 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/11449/305708 | - |
Descrição: dc.description | Rationale and Objectives: Hepatocellular carcinoma (HCC) treatment often requires transarterial chemoembolization (TACE). However, TACE efficacy is controversial in the presence of portal vein thrombosis (PVT). Although transarterial radioembolization (TARE) benefit was previously documented in PVT, neither the objective tumor response (OTR) after TARE with Iodine-131-lipiodol (131I-lipiodol) nor the PVT effect on the results of locoregional therapies was accurately measured in prospective clinical trials. The aim of this study was to compare OTR and survival obtained by TARE with 131I-lipiodol versus TACE in patients with cirrhosis and HCC, as well as between those with and without PVT. Materials and Methods: 33 patients were included, from whom 38 tumors were assessed. OTR was quantified by a special algorithm to measure hypervascular HCC tissue. Results: 19 tumors received each therapy. Nine subjects (27%) had PVT, most of them in the TARE group (p = 0.026). Mean OTR according to the tumor volumes was 24.2% ± 56% after TARE and 32.8% ± 48.9% after TACE, with no difference between the treatments (p = 0.616). Similar values were also observed between those with and without PVT (p = 0.704). Mean survival was 340 days and did not differ between the two treatments (p = 0.596), but was 194 days in PVT cases (p = 0.007). Conclusions: This is the first study in which OTR obtained by TARE with 131I-lipiodol is accurately measured. Additionally, PVT impact on survival after TARE and TACE was precisely documented. Although the TARE group had more PVT subjects (who had shorter survival), TARE and TACE achieved similar OTR and OS rates. | - |
Descrição: dc.description | Department of Internal Medicine Sao Paulo State University (UNESP) | - |
Descrição: dc.description | Center of Medical Physics and Radiation Protection Clinical Hospital at Botucatu School of Medicine-HC-FMB | - |
Descrição: dc.description | Department of Infectology Dermatology Imaging Diagnosis and Radiotherapy Sao Paulo State University (UNESP) | - |
Descrição: dc.description | Liver and Digestive Organs Transplantation Division Gastroenterology Department Clinical Hospital of Sao Paulo University - HCFMUSP | - |
Descrição: dc.description | Department of Gastroenterology General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area) | - |
Descrição: dc.description | Department of Internal Medicine Sao Paulo State University (UNESP) | - |
Descrição: dc.description | Department of Infectology Dermatology Imaging Diagnosis and Radiotherapy Sao Paulo State University (UNESP) | - |
Formato: dc.format | 1839-1848 | - |
Idioma: dc.language | en | - |
Relação: dc.relation | Academic Radiology | - |
???dc.source???: dc.source | Scopus | - |
Palavras-chave: dc.subject | Hepatocellular carcinoma | - |
Palavras-chave: dc.subject | Objective tumor response | - |
Palavras-chave: dc.subject | Portal vein thrombosis | - |
Palavras-chave: dc.subject | Transarterial chemoembolization | - |
Palavras-chave: dc.subject | Transarterial radioembolization | - |
Título: dc.title | Objective Tumor Response of Hepatocellular Carcinoma Obtained by Transarterial Radioembolization with Iodine-131-Lipiodol Versus Transarterial Chemoembolization for Patients with and without Portal Venous Thrombosis: A Controlled Interventional Trial | - |
Tipo de arquivo: dc.type | livro digital | - |
Aparece nas coleções: | Repositório Institucional - Unesp |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: